Navigation Links
NHP Reports 2009 First Quarter Results
Date:5/7/2009

e same period of 2008:

                             SELECTED FINANCIAL DATA
                    ($ in thousands, except per share amounts)


                                              Three Months Ended March 31,
                                           ---------------------------------
                                           2009     2008   $ Change % Change
                                           ----     ----   -------- --------

    Revenue                               $97,251  $85,270  $11,981     14.1%
    Income from Continuing Operations     $29,399  $22,940   $6,459     28.2%
    Net Income Attributable to NHP
     Common Stockholders                  $49,154  $35,393  $13,761     38.9%
    Net Income Attributable to NHP Common
     Stockholders Per Diluted Share         $0.47    $0.37    $0.10     27.0%
    Diluted FFO                           $61,569  $56,293   $5,276      9.4%
    Diluted FFO Per Share                   $0.57    $0.56    $0.01      1.8%
    Diluted FAD                           $61,427  $54,571   $6,856     12.6%
    Diluted FAD Per Share                   $0.57    $0.54    $0.03      5.6%

NON-GAAP FINANCIAL MEASURES

Diluted Funds From Operations ("FFO") and Diluted Funds Available for Distribution ("FAD") are non-GAAP measures that we believe are important to understanding our operations. We believe diluted FFO is an important supplemental measure of operating performance because it excludes the effects of depreciation and amortization and gains (losses) from sales of facilities (both of which are based on historical costs and which may be of limited relevance in evaluating current performance). We believe diluted FAD is an important supplemental measure of operating performance because, like diluted FFO, it excludes the effects of depreciation and amortization and gains (losses) from sales of facilities (both of which
'/>"/>

SOURCE Nationwide Health Properties, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
2. PLC Systems Reports First Quarter 2009 Results
3. Perrigo Reports Record Third Quarter
4. Symmetry Medical Reports First Quarter 2009 Financial Results
5. Orchid Cellmark Reports Improved First Quarter 2009 Financial Results
6. Labopharm Reports Results for First Quarter Fiscal 2009
7. Isis Reports Strong Financial Results and Highlights for First Quarter of 2009
8. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
9. Stereotaxis Reports First Quarter 2009 Financial Results
10. Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
11. The Ensign Group Reports First Quarter 2009 Earnings of $0.38 per Share; Reaffirms 2009 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... glioblastoma brain tumor cells that uses a modified poliovirus ... establish the proper dose level, researchers at Duke Cancer ... tested in an ongoing phase 1 study, capitalizes on ... receptors that work like magnets drawing the poliovirus, which ... investigational therapy, known as PVSRIPO, uses an engineered form ...
(Date:5/21/2013)... 2013 STAR (Sensory Therapies And ... with sensory challenges and the Sensory Processing Disorder ... and advocacy of Sensory Processing Disorder present Stumbling Blocks ... Improve Quality of Life, a two-hour lecture presented by ... , Learn a method that can aid in ...
(Date:5/21/2013)... As the summer season kicks off, ... camp or beginning practice for summer or fall sports. ... or sporting activities can begin. , To help parents during ... youth sports or camp physicals at just $29. ... review a child’s medical history, perform a physical exam and ...
(Date:5/21/2013)... Diehard soccer fans will definitely want to ... the game between Manchester City and Chelsea FC ... These two teams are highly decorated in the English Premiere ... to the Busch Stadium, home of the St. Louis Cardinals, ... time that a professional sporting event and non-baseball game will ...
(Date:5/21/2013)... 21 (HealthDay News) -- Urban elementary school children ... sleep problems and suffer academically, new research indicates. ... seven to nine, we found that compromised lung ... impaired academic performance," said study author Daphne ... behavior at Brown University,s Alpert Medical School in ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 3Health News:MedSpring Offers Affordable Youth Physicals for $29 2Health News:Manchester City vs. Chelsea FC Tickets: Cheap Concert Tickets has Slashed Prices on Manchester City vs. Chelsea FC Tickets at Busch Stadium in St. Louis, MO 2Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2
... Christian Davis Furman, M.D., M.S.P.H., vice chair for ... Medicine at the University of Louisville, has been selected ... Innovation Advisors Program. She is the only Kentuckian among ... of Columbia selected to participate. The ...
... New York (CCNY) whose research unites the divergent fields ... honored this month for his pioneering work in biomedical ... photonics. SPIE will present Dr. Robert Alfano, CUNY ... the first annual Britton Chance Biomedical Optics Award January ...
... FRIDAY, Jan. 6 (HealthDay News) -- If you,re 50 or ... screened for colorectal cancer, the American Society for Gastrointestinal Endoscopy ... cancers because most cases arise from precancerous growths in the ... exam and removed before they turn into cancer. Recent ...
... Fla. (Jan. 6, 2012) A malignancy-risk gene signature ... predictive and prognostic value for patients with early stage ... researchers at Moffitt Cancer Center in Tampa, Fla., who ... the Journal of the National Cancer Institute . ...
... Linagliptin (trade name: Trajenta) has been approved since August ... adults with type 2 diabetes mellitus whose elevated blood ... It is an option for patients who do not ... the drug metformin. Moreover, linagliptin can be added if ...
... Reinberg HealthDay Reporter , THURSDAY, Jan. 5 ... U.S. advisory panel,s recommendation to lower the threshold for ... once common in gasoline and house paint, can permanently ... Committee on Childhood Lead Poisoning Prevention voted to recommend ...
Cached Medicine News:Health News:UofL geriatrician selected for new federal Innovation Advisors Program 2Health News:CCNY's Robert Alfano wins first biomedical optics award 2Health News:CCNY's Robert Alfano wins first biomedical optics award 3Health News:Resolve to Take Colon Cancer Test, Experts Say 2Health News:Researchers find malignancy-risk gene signature for early-stage non-small cell lung cancer 2Health News:Added benefit of linagliptin is not proven 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 3
(Date:5/21/2013)... , May 21, 2013  Vasomedical, Inc. (OTC BB: ... the design, manufacture and sale of medical devices and in ... Dr. Jun Ma , President and CEO ... LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hotel. The Company,s presentation is scheduled to ...
(Date:5/21/2013)... Calif. , May 21, 2013   ... announced today the publication of study results involving ... CyberKnife® Robotic Radiosurgery System, the most widely used ... The study followed 304 patients for a median ... post-treatment and found that 97 percent of patients ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
... NEW HAVEN, Conn., Aug. 5 Rib-X ... company focused on the,discovery and development of ... announced today that company,representatives are giving three ... Research Conference on Medicinal Chemistry, August 3-8, ...
... Aug. 5 Nexgen Spine, a leading,developer of ... disc disease, announced today that it has received ... Disc in the European,Union., "We are delighted ... mark approval," said Alastair Clemow, Ph.D., President and ...
Cached Medicine Technology:Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 2Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 3Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
... The Vitros 950 provides power ... needs of high volume testing ... up to 900 results per ... store and perform the full ...
... Monitoring Market in 1981 with the introduction ... this system uses technology known as FPIA ... concentration in a patient. Therapeutic Drugs, used ... exhibit a narrow therapeutic range requiring close ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Architect i2000SR provides high productivity. Seamless integration optimize performance....
Medicine Products: